BMS-986142

DRUG5 trials

Sponsors

Bristol-Myers Squibb

Conditions

ArthritisHealthy AdultRheumatoid ArthritisSjögren's Syndrome

Phase 1

Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects

CompletedNCT02257151

Bristol-Myers SquibbHealthy Adult

Start: 2014-09-30End: 2015-08-31Updated: 2015-09-24

The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

CompletedNCT02832180

Bristol-Myers SquibbArthritis

Start: 2016-05-31End: 2016-10-31Updated: 2016-12-26

Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects

CompletedNCT02880670

Bristol-Myers SquibbArthritis

Start: 2016-08-31End: 2016-09-30Updated: 2016-11-16

Phase 2

Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis

CompletedNCT02638948

Bristol-Myers SquibbRheumatoid Arthritis

Start: 2016-02-16End: 2018-05-03Updated: 2019-05-28

Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

TerminatedNCT02843659

Bristol-Myers SquibbSjögren's Syndrome

Start: 2016-10-18End: 2017-07-24Updated: 2018-10-04

Related Papers

Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study.

2023-05-019 citations